Marshall Wace North America’s Tandem Diabetes Care TNDM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
– Sell
-3,643
Closed -$322K – 1775
2021
Q1
$322K Buy
3,643
+1,422
+64% +$132K ﹤0.01% 1302
2020
Q4
$213K Buy
+2,221
New +$229K ﹤0.01% 1221
2020
Q1
– Sell
-27,763
Closed -$1.66M – 1601
2019
Q4
$1.66M Sell
27,763
-158,547
-85% -$9.78M 0.01% 612
2019
Q3
$11M Buy
186,310
+66,298
+55% +$4.23M 0.06% 249
2019
Q2
$7.74M Sell
120,012
-10,825
-8% -$699K 0.05% 274
2019
Q1
$8.31M Buy
130,837
+26,873
+26% +$1.41M 0.06% 235
2018
Q4
$3.95M Sell
103,964
-183,332
-64% -$6.47M 0.04% 287
2018
Q3
$12.3M Buy
+287,296
New +$10M 0.08% 187
2018
Q2
– Sell
-150,525
Closed -$747K – 1685
2018
Q1
$747K Buy
+150,525
New +$485K ﹤0.01% 1066

Other funds holding TNDM

Marshall Wace North America's TNDM Position: Q2 2021 in Review

Marshall Wace North America sold out of Tandem Diabetes Care (TNDM) in Q2 2021, closing a stake of 3,643 shares — an estimated $322K sold.

Marshall Wace North America first reported a position in TNDM in Q1 2018 and held it in 9 quarters. The position peaked at $12.3M in Q3 2018. 303 funds tracked by Wall St. Rank hold TNDM as of Q2 2021.

  • Marshall Wace North America reported no remaining Tandem Diabetes Care position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 3,643 Tandem Diabetes Care shares in Q2 2021, an estimated $322K.
  • Marshall Wace North America first reported a position in Tandem Diabetes Care in Q1 2018 and held it in 9 quarters.
  • Marshall Wace North America's Tandem Diabetes Care position peaked at $12.3M in Q3 2018.
  • 303 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.